DOCSLIB.ORG

69292/2020/Estt-Ne Hr 5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

5 69292/2020/ESTT-NE_HR Index Sr. No. Particulars Page No. 1 General Billing Rules 2--11 2 Packages Detail 12--23 3 Room Rent 24--25 4 Consultation Charges. 26--32 5 CTVS PACKAGE ROCEDURES 33--35 6 CTVS PEDIATRIC 36--37 7 CATH ADULT PROCEDURES 38--39 8 EP STUDY PACKAGE PROCEDURES 40--41 9 PEDIATRIC CATH PROCEDURES 42--43 10 UROLOGY PROCEDURES 44--46 11 NEPHROLOGY PROCEDURES 47-52 12 VASCULAR SURGERY 53--54 13 GENERAL SURGERY PROCEDURE 55--62 14 NUEROLOGY PROCEDURES 63--67 15 UROLOGY 68--71 16 DENTAL PROCEDURES 72--78 17 DERMATALOGY PROCEDURES 79--82 18 ENT PROCEDURES 83--87 19 NEPHROLOGY 88--89 20 GYNECOLOGY PROCEDURES 90--93 21 LABORATORY TEST CHARGES 94-120 22 ONCOLOGY PROCEDURES 121-126 23 OPTHALMOLOGY PROCEDURES 127-130 24 PULMONOLOGY PROCEDURES 131-134 25 PAIN CLINIC CHARGES 135-136 26 PLASTIC SURGERY 137-141 27 PHYSIOTHERAPY CHARGES 142-144 28 MISC. & OTHER SERVICES 145-148 29 CARDIAC DIAGNOSTIC CHARGES 149-151 30 CT PROCEDURES 152-155 31 MRI PROCEDURES 156-162 32 X RAY PROCEDURES 163-166 33 ULTRASOUND PROCEDURES 167-169 34 DIAGNOSTIC NEUROLOGY 170-172 35 DIANG-HIS 173-174 36 BLOOD BANK 175-176 37 GASTROENTEROLOGY PACKAGES 177-178 38 GASTROENTEROLOGY 179-184 39 TRANSPLANT CHARGES 185-186 0 6 69292/2020/ESTT-NE_HR 40 ORTHOPAEDIC PACKAGES 187-189 41 ORTHOPAEDICS PROCEDURES 190-199 42 MAXILLOFACIAL SURGERY 200-206 43 ONCO SURGERY 207-209 44 INTERVENTIONAL RADIOLOGY & CARDIOLOGY 210-211 45 ANESTHESIA PROCEDURES 212-214 46 PSYCHOLOGY 215-216 1 7 69292/2020/ESTT-NE_HR GENERAL BILLING RULES & GUIDELINES 2 8 69292/2020/ESTT-NE_HR Registration and Admission Charges a) Onetime Registration charges of INR.100/- shall be charged to all new patients coming to Hospital for the first time. b) Onetime Admission charges of INR.2000/- shall be charged in all admission. Follow-up Visit policy for IPD patients a) One follow-up OPD Consultation of a surgical case shall be billed as zero consult. b) All patients coming for follow up in OPD within 6 days (to discuss the reports) shall be billed as zero consult. Triage Billing Policy a) Triage Bed Charges: Triage stay (Emergency) charges @ 1000/- per hour (First Hour Free) up to a maximum of eight hours. Beyond 8 hrs if the patient stays in the ER, charges shall be applicable as per Sharing Deluxe/opted room category. b) Triage stay shall not be more than 8 hours without justified approval from Head Emergency / Critical Care/Medical Superintendent. c) Patient is admitted as inpatient from Emergency, Triage bed charges shall not be levied. d) Patient is admitted as inpatient from Emergency, EMO charges shall not be levied. e) If patient getting discharge directly from triage and patient stay is less than 8 hours, all services shall be levied as per OPD rates. f) Triage tariff do not include EMO/ SR/ Specialty doctor Visit/ Investigation / Procedure/ Consumables / Medicines, which will be billed additionally. g) Visit charges of in house EMO will be INR. 500/-. If a Consultant visits Triage, the charges are as per the Pricing Policy and only one consultation visit either EMO/SR or Consultant shall be charged. 3 9 69292/2020/ESTT-NE_HR Billing Cycle a) Billing cycle will start from time of admission and is from 11:00 am to 11:00 am. Therefore 11:00 am is the checkout time for discharge. This policy however is not applicable in case of Day Care. b) First day charge as full day at the time of admission only. (Minimum 1-day charges applicable). c) Minimum half day charge is applicable for any admission (stay from 11 AM to 5 PM). Upto 5 PM of Stay will be billed1 as Half Day Stay and after 5 PM shall be billed as Full Day. Room Policy a) Room tariff includes standard fittings in the room according to the type of Occupancy / Laundry Services / House-keeping services. b) Room rent charges do not includes any professional fees like RMO Fee, Diet Charges, Dietician Visit, MRD charge and Equipment charges etc. c) Any additional Food & Beverage for anybody (Patient/Attendants) will be charged on MRP Basis. d) If the Patient’s Attendant retains the room while the Patient is in HDU / ICU /CRITICAL CARE AREAS, additional charges for the Room and Food & Beverage would be levied separately. e) In such cases Room would be provided subject to availability & approval from Admin Head. f) ICU Tariff does not include Specialty Doctors Visit / Ventilator / Investigations / Procedures / Consumables and Medicines. g) The Room charges do not include any Therapeutic procedure / Ventilator or Ventilator Initiation charges and Oxygen charges. h) When a patient is admitted through Emergency and the desired type of room is not available, then whichever type of room is available will be offered to Patient and charges will be applicable as per offered room type. 4 10 69292/2020/ESTT-NE_HR Room Charges Room Rent RATE CORONARY CARE UNIT ( CCU ) CHARGE 15800 DELUXE SUITE CHARGE 35000 GENERAL WARD CHARGE 6500 TWIN / DOUBLE SHARING 9000 SINGLE DELUXE ROOM 21500 SUITE 30200 PRESIDENTIAL SUIT 85000 HIGH DEPENDECY UNIT ( HDU ) CHARGE 10000 Medical History Assessment Charges One time charges of INR.1600 to be charged from all IP admissions except those who are admitted in Triage (Non admissions). TPA Evaluation Charges One time charges of INR.800 to be charged as TPA Evaluation charges from all IP admissions routed through TPA. Therapeutic Diet Charge Therapeutic Diet charges of INR. 1000 will be applicable once in every day during patient Stay in the hospital from each Inpatient. Sample Collection Charge Sample collection charges of INR. 500/- will be applicable daily during patient Stay in the hospital from each Inpatient and subject to the investigations. 5 11 69292/2020/ESTT-NE_HR IP Consultation policy a) Two consultations during the day will be applicable in addition to other specialty consultations if required. b) IPD Doctor Team Visiting Charge will vary depending upon bed category and seniority of the doctor. c) Emergency visits shall be charged at 2100 /- per visit (in between 8pm to 8am, holiday and Sundays) d) In case of ICU/Critical Areas: Critical Care Charges of Rs. 4500 per day will be charged in addition to the routine consultation charges. e) The charge of the other specialty consultation will be charged as actuals apart from the admitting doctor charges. Bed Transfer policy a) In the event of Bed Transfer during course of treatment, the higher category of bed charges will be charged. b) In case the Patient is transferred from Lower to Higher category of Room following the Surgery/ Procedure charge would be revised according to higher bed category. The bed charges and the doctor’s visit charges would be charged as per the higher room category from the day of admission. c) In case the Patient is transferred from Higher to lower category of room following surgery / procedure would be charged as per Higher Bed category. The bed charges and the doctor’s visit charges would be charged as per the higher room category from the day & time of transfer. d) If the patient is transferred to ICU during the course of IP stay, then the surgery / procedure charges shall remain same as per original Bed occupied charges. However, ICU charges will be levied during actual duration of stay in the ICU. e) In case, due to non-availability of room if patient is shifted to higher category in that case also charges will be applicable as per desired category and when the desired category becomes available, patient gets shifted there. f) Where a patient admitted to ICU bed directly then the charges for procedure and surgery will be in line with the rates applicable in sharing room, however if patient opted for higher category the surgery/procedure will be charged as per charges applicable to higher category of bed. 6 12 69292/2020/ESTT-NE_HR Policy Related to Surgery/Package/Procedure a) Packages are prepared after all permissible discounted minimal usage items for normal conditions cases wherein there is no detailed prescription. b) In case more than one or multiple package/procedure is performed in single/different sitting, will attract the full procedure/package charges. c) Package/Procedure will be charged as per opted bed category. d) In case of PTCA , if done in two sitting, procure charge of second sitting will be charged extra rest other component like drugs, consumables, investigation etc. will be charged on actuals. e) Packages are non-discountable f) Multiple procedure in different region will attract full procedure charges. g) Rs.20,000 is charges in case of emergency/holidays for Angioplasty. h) Rs.30,000 is charged additional to package cost in case of adult patient admitted under pediatric surgery. i) Bed side Procedure (Minor Procedures) would be charged as per rates defined for various room Categories in the price list. Advance Policy a) For Planned procedures 100% of the estimate amount to be collected as advanced. If 100% of the estimated amount has not been cleared / deposited then surgery clearance shall not be given. Surgery clearance shall be issued post the deposit of requisite advance. b) For Emergencies and non-procedure observation patients following advances to be taken, (Unless the consultant fills an estimate in this case 80% of estimate): Room Type Advance Amount slab Single INR. 30,000/- Double INR. 20,000/- ICU INR. 50,000/- 7 13 69292/2020/ESTT-NE_HR c) (TPA) Retail Customers/ Individual policy Holders: Advance to be taken (as per policies / Protocols set up by units) where in patients walks in without authorization letter.
Recommended publications
  • Embolization of Ruptured Ovarian Granulosa Cell Tumor Presenting As Acute Hemoperitoneum

    Embolization of Ruptured Ovarian Granulosa Cell Tumor Presenting As Acute Hemoperitoneum

    Published online: 2021-03-23 IR Snapshot Embolization of Ruptured Ovarian Granulosa Cell Tumor Presenting as Acute Hemoperitoneum A 56-year-old postmenopausal female peritoneal fluid with evidence of active Nasser Alhendi1,2, presented in shock state and abdominal contrast extravasation [Figure 1]. The exact Haitham Arabi2,3, distension. Contrast-enhanced computed origin of the mass could not be identified Raghad Alhindi1,4 tomography showed a large heterogeneous due to the presence of hemoperitoneum. 1Division of Vascular mass in the left adnexa surrounded by dense The patient was resuscitated with Interventional Radiology, Department of Medical Imaging, Ministry of National Guard‑Health Affairs, 2King Abdullah International Medical Research Center, 3Department of Pathology and Laboratory Medicine, Ministry of National Guard‑Health Affairs, 4Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia a b Figure 1: Axial pelvic contrast‑enhanced computed tomography scan in arterial phase (a) portal venous phase (b) large pedunculated heterogeneous mass arising from the uterine fundus/left adnexa, surrounded by extensive dense peritoneal fluid related to bleeding and showing internal contrast extravasation (white arrow) Address for correspondence: Dr. Nasser Alhendi, Department of Medical Imaging, Division of Vascular Interventional Radiology, King Abdulaziz Medical City, Riyadh, Saudi Arabia. E‑mail: dr_nasser1@hotmail. com Access this article online a b Website: www.arabjir.com Figure 2: Initial angiogram of left uterine artery demonstrates mildly hypertrophied distal branches (a) with focal DOI: 10.4103/AJIR.AJIR_42_18 contrast extravasation (a and b) (white arrows) Quick Response Code: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution- NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, How to cite this article: Alhendi N, Arabi H, as long as appropriate credit is given and the new creations Alhindi R.
  • Dengue–COVID-19 Coinfection: the First Reported Case in the Philippines

    Dengue–COVID-19 Coinfection: the First Reported Case in the Philippines

    Case Report/Case Series Dengue–COVID-19 coinfection: the first reported case in the Philippines Angyap Saipen,a Bernard Demot,a Lowella De Leona Correspondence to Angyap Lyn Saipen (email: [email protected]) The rainy season in the Philippines is from June to October; this is when the number of dengue cases typically increases. In 2020 during this time, the world was facing the threat of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection. Coronavirus disease 2019 (COVID-19) and dengue viral infections have similar presentations and laboratory findings, including fever and thrombocytopenia, and there have been reports of coinfection with SARS-CoV-2 and arthropod-borne virus. Here, we report a case of SARS-CoV-2–dengue virus coinfection in the Philippines in a female aged 62 years, whose early symptom was fever and who was positive for SARS-CoV-2 and positive for dengue. Early recognition of such coinfection is important so that proper measures can be taken in the management of the patient. engue fever is a mosquito-borne viral infection fever (highest recorded at 39.5 °C), with associated found mostly in tropical climates, including headache (frontoparietal in location, rated 5/10 and Dthe Philippines. The clinical manifestations of bandlike in character) and retro-orbital pain, general- dengue may include high-grade fever, headache, retro- ized body ache, myalgia and arthralgia. There was no orbital pain, muscle and joint pains, and rashes. In associated nausea, vomiting or blurring of vision. The 2019, the Philippines had one of the highest numbers patient had pain over the ankle joints, with no associ- of reported dengue cases among countries in Asia ated warmth or limitation of movement, and no rashes, and South-East Asia.1 According to the World Health cough or dyspnoea.
  • VDL Annual Report

    VDL Annual Report

    2010 Annual Report Table of Contents ISU VDL Mission Statement .......................................................................................................................... 3 VDPAM Organizational Chart ....................................................................................................................... 4 VDPAM External Advisory Board .................................................................................................................. 5 VDL Faculty List ............................................................................................................................................ 6 VDL Staff List ................................................................................................................................................ 7 New Tests Introduced ................................................................................................................................... 9 2010 Statistical Data ................................................................................................................................... 10 Accessions .............................................................................................................................................. 10 Tests ....................................................................................................................................................... 11 Submission Trends ................................................................................................................................
  • Oocyte Cryopreservation for Fertility Preservation in Postpubertal Female Children at Risk for Premature Ovarian Failure Due To

    Oocyte Cryopreservation for Fertility Preservation in Postpubertal Female Children at Risk for Premature Ovarian Failure Due To

    Original Study Oocyte Cryopreservation for Fertility Preservation in Postpubertal Female Children at Risk for Premature Ovarian Failure Due to Accelerated Follicle Loss in Turner Syndrome or Cancer Treatments K. Oktay MD 1,2,*, G. Bedoschi MD 1,2 1 Innovation Institute for Fertility Preservation and IVF, New York, NY 2 Laboratory of Molecular Reproduction and Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY abstract Objective: To preliminarily study the feasibility of oocyte cryopreservation in postpubertal girls aged between 13 and 15 years who were at risk for premature ovarian failure due to the accelerated follicle loss associated with Turner syndrome or cancer treatments. Design: Retrospective cohort and review of literature. Setting: Academic fertility preservation unit. Participants: Three girls diagnosed with Turner syndrome, 1 girl diagnosed with germ-cell tumor. and 1 girl diagnosed with lymphoblastic leukemia. Interventions: Assessment of ovarian reserve, ovarian stimulation, oocyte retrieval, in vitro maturation, and mature oocyte cryopreservation. Main Outcome Measure: Response to ovarian stimulation, number of mature oocytes cryopreserved and complications, if any. Results: Mean anti-mullerian€ hormone, baseline follical stimulating hormone, estradiol, and antral follicle counts were 1.30 Æ 0.39, 6.08 Æ 2.63, 41.39 Æ 24.68, 8.0 Æ 3.2; respectively. In Turner girls the ovarian reserve assessment indicated already diminished ovarian reserve. Ovarian stimulation and oocyte cryopreservation was successfully performed in all female children referred for fertility preser- vation. A range of 4-11 mature oocytes (mean 8.1 Æ 3.4) was cryopreserved without any complications. All girls tolerated the procedure well.
  • Severe Dengue Due to Secondary Hemophagocytic Lymphohistiocytosis

    Severe Dengue Due to Secondary Hemophagocytic Lymphohistiocytosis

    IDCases 8 (2017) 50–53 Contents lists available at ScienceDirect IDCases journal homepage: www.elsevier.com/locate/idcr Case report Severe dengue due to secondary hemophagocytic lymphohistiocytosis: A case study Ujjwayini Ray*, Soma Dutta, Susovan Mondal, Syamasis Bandyopadhyay Apollo Gleneagles Hospitals, 58, Canal Circular Road, Kolkata 70054, West Bengal, India A R T I C L E I N F O A B S T R A C T Article history: Received 17 March 2017 Dengue, transmitted by the mosquito Aedes aegypti affects millions of people worldwide every year. Received in revised form 25 March 2017 Dengue induced hemophagocytic lymphohistiocytosis (HLH) is a serious condition and may prove fatal if Accepted 25 March 2017 not detected early and treated appropriately. Diagnosis of HLH is challenging and usually missed as Available online xxx clinical and laboratory findings are nonspecific. Moreover, the pathophysiology of the systemic inflammatory response syndrome and/or sepsis is remarkably similar to HLH. Secondary HLH following Keywords: infection by the dengue virus is now being increasingly recognized as a cause of severe form of the Bicytopenia disease. We report a case of dengue associated HLH in an otherwise healthy person who deteriorated Dengue during the course of hospitalization. A disproportionately high ferritin level and persistent bicytopenia Hemophagocytic lymphohistiocytosis prompted investigations for HLH. Diagnosis of dengue fever with virus-associated hemophagocytic (HLH) Infection syndrome was established according to the diagnostic criteria laid down by the Histiocyte Society. We discuss the diagnosis and management of this complex case and try to generate awareness about dengue Intravenous immunoglobulin G induced HLH as one of the possible causes for severe manifestations of this infection © 2017 The Authors.
  • 2014-2015 Distinction Track Program Annual Report

    2014-2015 Distinction Track Program Annual Report

    ACADEMIC YEAR 2014-2015 UNDERGRADUATE MEDICAL EDUCATION DISTINCTION TRACKS PROGRAM ANNUAL REPORT UNDERGRADUATE MEDICAL EDUCATION, SCHOOL OF MEDICINE M. ANN SHAW, MD, MA, FACP CHAIR, DISTINCTION TRACK ADVISING AND STEERING COMMITTEE Table of Contents Introduction ............................................................................................................................................................................ 2 Distinction Tracks Program Docket ..................................................................................................................................... 2 Individual Track Directors (Also advisory members of Distinction Track Advising and Steering Committee) ............... 2 Distinction Track Advising and Steering Committee (DTASC) Members ........................................................................ 2 Student Participants ........................................................................................................................................................ 2 Organizational Achievements ................................................................................................................................................. 3 Programatic Evaluation ........................................................................................................................................................... 4 2015 Distinction Tracks Program Graduating Student Focus Group, Summary Report ..................................................... 5 2015 Distinction Tracks
  • Total Abdominal Hysterectomy (TAH)

    Total Abdominal Hysterectomy (TAH)

    Total Abdominal Hysterectomy (TAH) Technique Procedure involves the removal of the uterus and cervix. The decision whether or not to remove the fallopian tubes and ovaries is a separate decision. If the ovaries are removed, the procedure name includes the term bilateral salpingoophorectomy (BSO). Incisions An incision is made on the abdomen for this procedure. The size of the incision is determined by the size of your uterus and the abdominal exposure needed. The incision will either by vertical (from the belly button down to the pubic bone) or horizontal ("bikini cut"). Operative Time Operative times vary greatly depending on the findings at the time of surgery. Your surgeon will proceed with safety as his/her first priority. Average times range from 45-120 minutes. Anesthesia Spinal anesthesia or General anesthesia Preoperative Care Nothing by mouth after midnight The procedure is usually scheduled immediately after your menstrual period. Hospital Stay Inpatient stay for 2-3 days after the surgery Postoperative Care These guidelines are intended to give you a general idea of your postoperative course. Since every patient is unique and has a unique procedure, your recovery may differ. Anti-inflammatory pain medicine is usually required for the first several days to manage soreness and inflammation. Narcotic pain medicine will be provided to assist with the discomfort from the incisions. Driving is allowed after your procedure only when you do not require the narcotic pain medicine to manage your pain. Patients may return to work in 4-6 weeks following the procedure. Incisions may bruise but they should not become red or inflamed.
  • THE AMERICAN JOURNAL of CANCER a Continuation of the Journal of Cancer Research

    THE AMERICAN JOURNAL of CANCER a Continuation of the Journal of Cancer Research

    THE AMERICAN JOURNAL OF CANCER A Continuation of The Journal of Cancer Research VOLUMEXVI MAY, 1932 NUMBER3 OVARIAN NEOPLASMS W. BLAIR BELL AND M. M. DATNOW In the first part of this communication l some points in the pathology of ovarian neoplasms were discussed. Here we shall first consider certain aspects of the clinical features associated with them. These cover so large a range of connected phenomena and conditions-namely, the symptoms and physical signs in a variety of circumstances which are related to the size and position, the complications, and the biological nature of the tumour concerned- that it will be neither possible, nor indeed desirable, to present a complete study in this place. Afterwards we shall examine some general principles in regard to the treatment of these neoplasms, especially in relation to the pathological and clinical features pre- sented, and to the age and condition of the patient. I1 CLINICAL FEATURES It is somewhat difficult to collate statistical information on a scale large enough to enable us to draw definite conclusions, even in respect of the average age and parity of the patients affected, for such figures do not seem always to have interested the collectore of 1 This paper, which is a continuation of that published in an earlier number of this JOURNAL(16: 1, 1932), likewise contains the substance (amplified in regard to statistics by M. M. Datnow) of the Introduction by W. Blair Bell to the Discussion on the subject at the British Congress of Obstetrics and Gynaecology held in Glasgow on April 21, 22 and 23, 1931, for an account of which see Journal of Obstetrics and Gynaecology of the British Empire, 38: 279, 1931.
  • Surgical Findings and Outcomes in Premenopausal Breast Cancer

    Surgical Findings and Outcomes in Premenopausal Breast Cancer

    Original Article Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Society of Gynecologic Surgeons Fellows Pelvic Research Network Lara F. B. Harvey, MD, MPH, Vandana G. Abramson, MD, Jimena Alvarez, MD, Christopher DeStephano, MD, MPH, Hye-Chun Hur, MD, Katherine Lee, MD, Patricia Mattingly, MD, Beau Park, MD, Carolyn Piszczek, MD, Farinaz Seifi, MD, Mallory Stuparich, MD, and Amanda Yunker, DO, MSCR From the Division of Minimally Invasive Gynecology, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee (Drs. Harvey and Yunker), Division of Hematology/Oncology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee (Dr. Abramson), Department of Obstetrics and Gynecology, Advocate Lutheran General Hospital, Park Ridge, Illinois (Dr. Alvarez), Department of Medical and Surgical Gynecology, Mayo Clinic, Jacksonville, Florida (Dr. DeStephano), Division of Minimally Invasive Gynecology, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (Dr. Hur), Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana (Dr. Lee), Division of Gynecologic Specialty Surgery, Department of Obstetrics and Gynecology, Columbia University Medical Center, New York-Presbyterian Hospital, New York, New York (Dr. Mattingly), Department of Obstetrics and Gynecology, Mayo Clinic Arizona, Phoenix, Arizona (Dr. Park), Division of Gynecologic
  • Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays

    Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays

    diagnostics Article Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays Li Kiang Tan 1, Wing Yan Wong 1, Hui Ting Yang 1, Roland G. Huber 2 , Peter J. Bond 2,3, Lee Ching Ng 1,4, Sebastian Maurer-Stroh 2,3 and Hapuarachchige Chanditha Hapuarachchi 1,* 1 Environmental Health Institute, National Environment Agency, Singapore 38667, Singapore; [email protected] (L.K.T.); [email protected] (W.Y.W.); [email protected] (H.T.Y.); [email protected] (L.C.N.) 2 Bioinformatics Institute, Agency for Science, Technology and Research, Singapore 138671, Singapore; [email protected] (R.G.H.); [email protected] (P.J.B.); [email protected] (S.M.-S.) 3 Department of Biological Sciences, National University of Singapore, Singapore 117558, Singapore 4 School of Biological Sciences, Nanyang Technological University, Singapore 639798, Singapore * Correspondence: [email protected]; Tel.: +65-65115335; Fax: +65-65115339 Received: 7 November 2019; Accepted: 23 December 2019; Published: 24 December 2019 Abstract: Dengue virus (DENV) and Zika virus (ZIKV) are flaviviruses of public health relevance. Both viruses circulate in the same endemic settings and acute infections generally manifest similar symptoms. This highlights the importance of accurate diagnosis for clinical management and outbreak control. One of the commonly used acute diagnostic markers for flaviviruses is nonstructural protein 1 (NS1). However, false positives due to antigenic cross-reactivity have been reported between DENV and ZIKV infections when using DENV NS1 antigen (NS1 Ag) detection assays in acute cases. Therefore, we investigated the lowest detectable virus titres and cross-reactivity of three commercial dengue NS1 Ag rapid assays and two ELISAs for different flaviviruses.
  • Endocrine Abstracts Vol 62

    Endocrine Abstracts Vol 62

    Endocrine Abstracts April 2019 Volume 62 ISSN 1479-6848 (online) Society for Endocrinology Endocrine Update 2019 published by Online version available at bioscientifi ca www.endocrine-abstracts.org Volume 62 Endocrine Abstracts April 2019 Society for Endocrinology: Endocrine Update 2019 08–10 April 2019 Programme Chairs: Dr James Ahlquist (Essex) Dr Peter Taylor (Cardiff) Abstract Markers: Dr Simon Aylwin (London) Dr Kristien Boelaert (Birmingham) Dr Karin Bradley (Bristol) Dr Andrew Lansdown (Cardiff) Dr Daniel Morganstein (London) Dr Helen Turner (Oxford) Professor Bijay Vaidya (Exeter) Dr Nicola Zammitt (Lasswade) Society for Endocrinology: Endocrine Update 2019 CONTENTS Society for Endocrinology: Endocrine Update 2019 NATIONAL CLINICAL CASES Oral Communications . ...................................... OC1–OC10 Poster Presentations . ....................................... P01–P73 CLINICAL UPDATE Workshop A: Disorders of the hypothalamus and pituitary . WA1–WA11 Workshop B: Disorders of growth and development . WB1–WB3 Workshop C: Disorders of the thyroid gland ..................................... WC1–WC10 Workshop D: Disorders of the adrenal gland ..................................... WD1–WD16 Workshop E: Disorders of the gonads . ..................................... WE1–WE10 Workshop F: Disorders of the parathyroid glands, calcium metabolism and bone . WF1–WF3 Workshop G: Disorders of appetite and weight . WG1–WG2 Workshop H: Miscellaneous endocrine and metabolic disorders . WH1–WH9 Additional Cases . .....................................
  • Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at Least After 5 Days of Infection

    Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at Least After 5 Days of Infection

    Research Article Anatomy Physiol Biochem Int J Volume 4 Issue 2- February 2018 Copyright © All rights are reserved by Sudipta Poddar DOI: 10.19080/APBIJ.2017.04.555632 Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at least after 5 Days of Infection Sudipta Poddar* and Amiya Kumar Hati Department of Medical Physiology, Lincoln University College, Malaysia Submission: January 01, 2017; Published: February 09, 2018 *Corresponding author: Sudipta Poddar, Department of Medical Physiology, Lincoln University College, 47301, Petaling Jaya, Malaysia; Email: Abstract Objectives: The objective of this paper is to detect the NS1 antigen beyond 5 days of infection in serologically confirmed dengue cases in whom both NS1 antigen and IgG and IgM antibodies were assessed. Methods: Out of a total of 1037 suspected persons 257 i.e. 24.78% were dengue reactive in 2013 and 2014. Dengue cases were diagnosed in the laboratory from suspected patients by dengue specific IgG, IgM antibodies and NS1 antigen. NS1 antigen and IgG antibodies were monitored in 220 (194+26) suspected dengue cases where interpretation was possible to detect NS1 beyond 5 days of infection. This study of detection of NS1 antigen in serologically confirmed dengue cases at least after 5 days of infection. Results: Among this 220 cases 86 (80+6) were confirmed dengue cases. Out of these 86 cases NS1 antigen was found beyond 5 days of infection in 15 i.e. 17.44%. Conclusion: It would be reasonable to believe that many such cases would be found in the category I where only NS1 was tested. Hence for getting the information on NS1 antigen beyond 5 days all three serological tests (NS1 antigen, IgG and IgM antibodies) should be performed.